Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hu, B.; Guo, H.; Zhou, P.; Shi, Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021, 19, 141–154. [Google Scholar] [CrossRef] [PubMed]
- Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.T.; Leung, K.; Leung, G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet 2020, 395, 689–697. [Google Scholar] [CrossRef] [Green Version]
- Dong, E.; Du, H.; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis 2020, 20, 533–534. [Google Scholar] [CrossRef]
- Han, F.; Liu, Y.; Mo, M.; Chen, J.; Wang, C.; Yang, Y.; Wu, J. Current treatment strategies for COVID-19 (Review). Mol. Med. Rep. 2021, 24, 858. [Google Scholar] [CrossRef]
- Aleem, A.; Kothadia, J.P. Remdesivir. In StatPearls; StatPearls publicing: Treasure Island, FL, USA, 2022. [Google Scholar]
- Zhao, L.; Li, S.; Zhong, W. Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review. Front. Pharm. 2022, 13, 840639. [Google Scholar] [CrossRef]
- Agarwal, A.; Rochwerg, B.; Lamontagne, F.; Siemieniuk, R.A.; Agoritsas, T.; Askie, L.; Lytvyn, L.; Leo, Y.S.; Macdonald, H.; Zeng, L.; et al. A living WHO guideline on drugs for COVID-19. BMJ 2020, 370, m3379. [Google Scholar] [CrossRef]
- Agostini, M.L.; Pruijssers, A.J.; Chappell, J.D.; Gribble, J.; Lu, X.; Andres, E.L.; Bluemling, G.R.; Lockwood, M.A.; Sheahan, T.P.; Sims, A.C.; et al. Small-Molecule Antiviral beta-d-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J. Virol. 2019, 93, e01348-19. [Google Scholar] [CrossRef] [Green Version]
- Wahl, A.; Gralinski, L.E.; Johnson, C.E.; Yao, W.; Kovarova, M.; Dinnon, K.H., 3rd; Liu, H.; Madden, V.J.; Krzystek, H.M.; De, C.; et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021, 591, 451–457. [Google Scholar] [CrossRef]
- Malone, B.; Campbell, E.A. Molnupiravir: Coding for catastrophe. Nat. Struct. Mol. Biol. 2021, 28, 706–708. [Google Scholar] [CrossRef]
- Owen, D.R.; Allerton, C.M.N.; Anderson, A.S.; Aschenbrenner, L.; Avery, M.; Berritt, S.; Boras, B.; Cardin, R.D.; Carlo, A.; Coffman, K.J.; et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 2021, 374, 1586–1593. [Google Scholar] [CrossRef]
- Hilgenfeld, R. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 2014, 281, 4085–4096. [Google Scholar] [CrossRef] [Green Version]
- Takashita, E.; Yamayoshi, S.; Simon, V.; van Bakel, H.; Sordillo, E.M.; Pekosz, A.; Fukushi, S.; Suzuki, T.; Maeda, K.; Halfmann, P.; et al. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022, 387, 468–470. [Google Scholar] [CrossRef]
- Agenzia Italiana del Farmaco. Uso Degli Antivirali Orali per COVID-19. Available online: https://www.aifa.gov.it/uso-degli-antivirali-orali-per-COVID-19 (accessed on 15 September 2022).
- Bernal, A.J.; da Silva, M.M.G.; Musungaie, D.B.; Kovalchuk, E.; Gonzalez, A.; Reyes, V.D.; Martin-Quiros, A.; Caraco, Y.; Williams-Diaz, A.; Brown, M.L.; et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N. Engl. J. Med. 2022, 386, 509–520. [Google Scholar] [CrossRef]
- Arribas, J.R.; Bhagani, S.; Lobo, S.M.; Khaertynova, I.; Mateu, L.; Fishchuk, R.; Park, W.Y.; Hussein, K.; Kim, S.W.; Ghosn, J.; et al. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with COVID-19. NEJM Evid. 2022, 1, EVIDoa2100044. [Google Scholar] [CrossRef]
- Hammond, J.; Leister-Tebbe, H.; Gardner, A.; Abreu, P.; Bao, W.; Wisemandle, W.; Baniecki, M.; Hendrick, V.M.; Damle, B.; Simon-Campos, A.; et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022, 386, 1397–1408. [Google Scholar] [CrossRef]
- Team, C.C.-R. SARS-CoV-2 B.1.1.529 (Omicron) Variant—United States, 1–8 December 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1731–1734. [Google Scholar] [CrossRef]
- Najjar-Debbiny, R.; Gronich, N.; Weber, G.; Khoury, J.; Amar, M.; Stein, N.; Goldstein, L.H.; Saliba, W. Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clin. Infect. Dis. 2022, ciac443. [Google Scholar] [CrossRef]
- De Vito, A.; Colpani, A.; Bitti, A.; Zauli, B.; Meloni, M.C.; Fois, M.; Denti, L.; Bacciu, S.; Marcia, C.; Maida, I.; et al. Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: A real-life experience. J. Med. Virol. 2022, 94, 5582–5588. [Google Scholar] [CrossRef]
- Taylor, C.A.; Whitaker, M.; Anglin, O.; Milucky, J.; Patel, K.; Pham, H.; Chai, S.J.; Alden, N.B.; Yousey-Hindes, K.; Anderson, E.J.; et al. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status—COVID-NET, 14 States, July 2021–January 2022. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 466–473. [Google Scholar] [CrossRef]
- Castilla, J.; Guevara, M.; Miqueleiz, A.; Baigorria, F.; Ibero-Esparza, C.; Navascués, A.; Trobajo-Sanmartín, C.; Martínez-Baz, I.; Casado, I.; Burgui, C.; et al. Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. J. Clin. Med. 2021, 10, 2608. [Google Scholar] [CrossRef] [PubMed]
- Shields, A.M.; Burns, S.O.; Savic, S.; Richter, A.G. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J. Allergy Clin. Immunol. 2021, 147, 870–875.e871. [Google Scholar] [CrossRef] [PubMed]
- Delavari, S.; Abolhassani, H.; Abolnezhadian, F.; Babaha, F.; Iranparast, S.; Ahanchian, H.; Moazzen, N.; Nabavi, M.; Arshi, S.; Fallahpour, M.; et al. Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. J. Clin. Immunol. 2021, 41, 345–355. [Google Scholar] [CrossRef] [PubMed]
- Passamonti, F.; Cattaneo, C.; Arcaini, L.; Bruna, R.; Cavo, M.; Merli, F.; Angelucci, E.; Krampera, M.; Cairoli, R.; Della Porta, M.G.; et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol. 2020, 7, e737–e745. [Google Scholar] [CrossRef]
- Wong, C.K.H.; Au, I.C.H.; Lau, K.T.K.; Lau, E.H.Y.; Cowling, B.J.; Leung, G.M. Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: An observational study. medRxiv 2022. medRxiv:2022.2005.2019.22275291. [Google Scholar]
Total (n = 257) | Molnupiravir (n = 146) | Nirmatrelvir/Ritonavir (n = 111) | p-Value | |
---|---|---|---|---|
Sex (n, %) | ||||
- Male | 124 (48.2) | 77 (52.7) | 47 (42.3) | 0.098 |
- Female | 133 (51.7) | 69 (47.2) | 64 (57.6) | |
Age (years; median, IQR) | 64 (52–75) | 70 (59–79) | 60 (40–67) | <0.001 |
Age (years; n, %) | ||||
- 19–65 | 140 (54.5) | 62 (42.5) | 78 (70.3) | <0.001 |
- >65 | 117 (45.5) | 84 (57.5) | 33 (29.7) | |
Comorbidities | ||||
- BMI ≥ 30 | 52 (20.2) | 23 (15.7) | 29 (26.1) | <0.05 |
- Chronic kidney disease | 14 (5.4) | 11 (7.5) | 3 (2.7) | 0.091 |
- Uncontrolled diabetes mellitus | 18 (7.0) | 13 (8.9) | 5 (4.5) | 0.171 |
- Immunodeficiency | 139 (54.1) | 72 (49.3) | 66 (59.5) | 0.085 |
- Chronic heart disease | 73 (28.4) | 59 (40.4) | 14 (12.6) | <0.001 |
- Chronic liver disease | 4 (1.6) | 4 (2.7) | 0 (0.0) | 0.136 |
- Severe chronic lung disease | 24 (9.3) | 18 (12.3) | 6 (5.4) | 0.059 |
- Neurodegenerative disorder | 9 (3.5) | 7 (4.8) | 2 (1.8) | 0.472 |
Number of comorbidities | ||||
- 0 | 10 (3.9) | 4 (2.7) | 6 (5.4) | 0.336 |
- 1 | 175 (68.1) | 88 (60.3) | 87 (78.4) | <0.01 |
- 2 | 61 (23.7) | 45 (30.8) | 16 (26.2) | <0.01 |
- ≥3 | 11 (4.3) | 9 (6.2) | 2 (1.8) | 0.121 |
MASS score # (median, IQR) | 3 (2–3) | 3 (2–3) | 3 (2.3) | 0.694 |
SARS-CoV-2 vaccination received * (n, %) | 247 (96.1) | 138 (94.5) | 109 (98.2) | 0.195 |
Molnupiravir (n = 146) | Nirmatrelvir/Ritonavir (n = 111) | p-Value | |
---|---|---|---|
Diarrhea | 4 (2.7%) | 2 (1.8%) | 0.701 |
Dizziness | 1 (0.7%) | 0 (0.0%) | 1.000 |
Dysgeusia | 4 (2.7%) | 10 (9.0%) | <0.05 |
Headache | 2 (1.7%) | 2 (1.8%) | 1.000 |
Nausea | 2 (1.7%) | 4 (3.6%) | 0.407 |
Seizure | 1 (0.7%) | 0 (0.0%) | 1.000 |
Skin rash | 1 (0.7%) | 1 (0.9%) | 1.000 |
Vomit | 1 (0.7%) | 0 (0.0%) | 1.000 |
Discontinuation of treatment | 2 (1.7%) | 0 (0.0%) | 0.507 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gentile, I.; Scotto, R.; Schiano Moriello, N.; Pinchera, B.; Villari, R.; Trucillo, E.; Ametrano, L.; Fusco, L.; Castaldo, G.; Buonomo, A.R.; et al. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Vaccines 2022, 10, 1731. https://doi.org/10.3390/vaccines10101731
Gentile I, Scotto R, Schiano Moriello N, Pinchera B, Villari R, Trucillo E, Ametrano L, Fusco L, Castaldo G, Buonomo AR, et al. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Vaccines. 2022; 10(10):1731. https://doi.org/10.3390/vaccines10101731
Chicago/Turabian StyleGentile, Ivan, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, and et al. 2022. "Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study" Vaccines 10, no. 10: 1731. https://doi.org/10.3390/vaccines10101731
APA StyleGentile, I., Scotto, R., Schiano Moriello, N., Pinchera, B., Villari, R., Trucillo, E., Ametrano, L., Fusco, L., Castaldo, G., Buonomo, A. R., & Federico II COVID Team. (2022). Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Vaccines, 10(10), 1731. https://doi.org/10.3390/vaccines10101731